Deals channel feed

Mus­tang Bio to sell Mass­a­chu­setts CAR-T man­u­fac­tur­ing fa­cil­i­ty

Last year
Cell/Gene Tx
Manufacturing

Eye­Point sells re­main­ing rights to eye im­plant, piv­ots to tack­le an­ti-VEG­Fs

Last year
R&D

As­traZeneca beefs up cell ther­a­py tool kit with gene edit­ing deal

Last year
Cell/Gene Tx

Am­gen's CEO says he's 'con­fi­den­t' their $28B deal with Hori­zon can close de­spite FTC law­suit

Last year
Law

SPAC for 2025 BLA: Non-vi­ral gene ther­a­py biotech en­Gene, steered by ex-Myth­ic lead­ers, finds For­bion blank check

Last year
Startups
Cell/Gene Tx

Lil­ly’s Pre­vail taps Jen­nifer Doud­na's spin­out Scribe Ther­a­peu­tics for neu­ro ge­net­ic med­i­cines

Last year
Startups
Cell/Gene Tx

Astel­las, Sony part­ner up for an­ti­body-drug con­ju­gate plat­form to cre­ate 'bet­ter per­form­ing' drugs

Last year
R&D

FTC sues to block $28B Am­gen-Hori­zon deal, in move that will send shock­waves through bio­phar­ma M&A

Last year

UniQure sells part of Hem­genix roy­al­ty for $400M cash

2 years ago
Financing

Adding to ADC port­fo­lio, As­traZeneca en­ters po­ten­tial $600M li­cens­ing deal with Chi­nese start­up

2 years ago

Italy's An­geli­ni Phar­ma teams up with JCR on blood-brain bar­ri­er deal

3 years ago
R&D

BioN­Tech and Mati­nas end oral mR­NA de­liv­ery col­lab­o­ra­tion

3 years ago
R&D

Ex­clu­sive: Af­ter win­ning le­gal bat­tle, for­mer Phase­Bio in­vestor finds US buy­er for its PhI­II drug to re­verse Bril­in­ta

3 years ago

CRO deal space con­tin­ues to buzz as Gen­e­sis Drug Dis­cov­ery buys JSS Med­ical Re­search

3 years ago
Outsourcing
Manufacturing

CRO Sy­neos Health to be ac­quired by a group of pri­vate eq­ui­ty firms for $7B+

3 years ago
Outsourcing
Manufacturing

So­bi swoops in with $1.7B buy­out for a biotech with an ap­proved JAK in­hibitor, but low on cash

3 years ago

Bay­er fol­lows No­var­tis' foot­steps in ink­ing ra­dio­phar­ma pact with Bi­cy­cle, pay­ing $45M cash up­front

3 years ago

Am­gen en­lists TCR start­up TScan to work on Crohn's in deal po­ten­tial­ly worth $500M+

3 years ago

Gilead­'s M&A streak car­ries on with buy­out of pri­vate PARP1, au­toim­mune biotech

3 years ago
Startups

Roche hands Chi­nese biotech $70M for HER2 drug that can go to the brain

3 years ago
China

Bio­Phar­ma So­lu­tions sold for $4B+ to two pri­vate eq­ui­ty firms

3 years ago
Pharma
Manufacturing

Am­gen and En­tera Bio call off oral drug de­liv­ery part­ner­ship af­ter four years

3 years ago
Pharma

Lund­beck out-li­cens­es three can­di­dates to Cam­bridge biotech

3 years ago
R&D

Ei­sai’s can­cer drug Halaven at the cen­ter of $2B pact with Bliss­Bio, like its Bris­tol My­ers ADC deal

3 years ago
China
Pharma
First page Previous page 34353637383940 Next page Last page
A service from the Financial Times